DE69411143T2 - Tryptamin analoge mit 5-ht1d selektivität - Google Patents

Tryptamin analoge mit 5-ht1d selektivität

Info

Publication number
DE69411143T2
DE69411143T2 DE69411143T DE69411143T DE69411143T2 DE 69411143 T2 DE69411143 T2 DE 69411143T2 DE 69411143 T DE69411143 T DE 69411143T DE 69411143 T DE69411143 T DE 69411143T DE 69411143 T2 DE69411143 T2 DE 69411143T2
Authority
DE
Germany
Prior art keywords
ht1d
4alkyl
chain
selectivity
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69411143T
Other languages
English (en)
Other versions
DE69411143D1 (de
Inventor
Richard Glennon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allelix Biopharmaceuticals Inc
Virginia Commonwealth University
Original Assignee
Allelix Biopharmaceuticals Inc
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allelix Biopharmaceuticals Inc, Virginia Commonwealth University filed Critical Allelix Biopharmaceuticals Inc
Publication of DE69411143D1 publication Critical patent/DE69411143D1/de
Application granted granted Critical
Publication of DE69411143T2 publication Critical patent/DE69411143T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69411143T 1993-09-01 1994-08-31 Tryptamin analoge mit 5-ht1d selektivität Expired - Fee Related DE69411143T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11500393A 1993-09-01 1993-09-01
PCT/CA1994/000476 WO1995006638A1 (en) 1993-09-01 1994-08-31 Tryptamine analogs with 5-ht1d selectivity

Publications (2)

Publication Number Publication Date
DE69411143D1 DE69411143D1 (de) 1998-07-23
DE69411143T2 true DE69411143T2 (de) 1998-10-22

Family

ID=22358755

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69411143T Expired - Fee Related DE69411143T2 (de) 1993-09-01 1994-08-31 Tryptamin analoge mit 5-ht1d selektivität

Country Status (7)

Country Link
EP (1) EP0666847B1 (de)
JP (1) JPH08506357A (de)
AT (1) ATE167471T1 (de)
AU (1) AU685837B2 (de)
CA (1) CA2147991A1 (de)
DE (1) DE69411143T2 (de)
WO (1) WO1995006638A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724933A1 (fr) * 1994-09-22 1996-03-29 Pf Medicament Nouveaux ethers aromatiques derives d'indoles utiles comme medicaments
US5654431A (en) * 1996-05-30 1997-08-05 Meng; Qingchang 5-alkoxy tryptamine derivatives
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
DK1379239T3 (da) 2001-03-29 2008-01-07 Lilly Co Eli N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
KR100411599B1 (ko) * 2001-10-23 2003-12-18 동방에프티엘 주식회사 5-치환된 인돌 유도체의 제조방법
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
AU2021302692A1 (en) * 2020-06-30 2023-01-19 Reunion Neuroscience Canada Inc. Tryptamine prodrugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317560A (en) * 1963-01-03 1967-05-02 Philips Corp Indol-3-yl alkylguanidine derivatives
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB9103770D0 (en) * 1991-02-22 1991-04-10 Glaxo Group Ltd Chemical compounds
EP0593513B1 (de) * 1991-06-21 1998-10-28 Smithkline Beecham Plc Tryptamin analoga, ihre herstellung und anwendung als 5-ht1-artige rezeptoren oder 5-ht2 rezeptor agonisten

Also Published As

Publication number Publication date
EP0666847B1 (de) 1998-06-17
DE69411143D1 (de) 1998-07-23
JPH08506357A (ja) 1996-07-09
AU7528594A (en) 1995-03-22
WO1995006638A1 (en) 1995-03-09
CA2147991A1 (en) 1995-03-09
EP0666847A1 (de) 1995-08-16
ATE167471T1 (de) 1998-07-15
AU685837B2 (en) 1998-01-29

Similar Documents

Publication Publication Date Title
ATE121389T1 (de) Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen.
ES2058614T3 (es) 1,2-ciclohexilaminoarilaminadas utiles como agentes analgesicos.
DE69418639D1 (de) Sulfonat- und Carbamatderivate von 3-aroyl-benzo(beta)Thiophenen
ES2133416T3 (es) Ligandos de subtipos de receptores de dopamina.
DE3889536D1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
DE69411143D1 (de) Tryptamin analoge mit 5-ht1d selektivität
DE3371785D1 (en) Novel crystal modifications, processes for their production, and pharmaceutical preparations containing them
CA2188798A1 (en) Tryptamine Derivatives as 5-HT-1D Receptor Ligands
AU587054B2 (en) Novel pharmaceutical compositions intended to the treatment of neuropathies and insuring the nervous regeneration
ES8502998A1 (es) Procedimiento para la preparacion de nuevas b-carbolinas substituidas.
EP0328634A4 (en) Pharmaceutical compositions for the treatment of psoriasis
DK0399185T3 (da) Fremgangsmåde til formindskelse af svovlindholdet i organiske sulfider
PT86619A (pt) Process for preparing alkylmelatonins
ES2077561T3 (es) Proceso para la modificacion de un tamiz molecular.
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
ATE114468T1 (de) Ethyl-(+)-apovincaminat zur behandlung der demyelinisierung klinischer erscheinungen autoimmunen ursprungs.
SE8404334D0 (sv) 16-fluoro-16,17-didehydro-prostanoids and process for their preparation
DK0401093T3 (da) Hidtil ukendte pyrrolidonderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende disse
EP0266665A3 (en) Treatment of inflammatory articular diseases
IT8723036A0 (it) Procedimento per la raffinazione del carbone mediante agglomerazione selettiva.
NO950114L (no) Amylin-antagonister og agonister
PT746556E (pt) Compostos triciclicos com afinidade para o receptor 5-ht1a
IT1031922B (it) Procedimento per la produzione di solfuro di carbonio da id rocarburi e zolfo
ES2028221T3 (es) Procedimiento para la obtencion declorotiolformiatos.
YU45087A (en) Process for neutralizing sulphur compounds by adding ammonia, with purpose for lowering the point of waste gasses condensation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee